References
1. Walensky RP, Paltiel AD, Losina E, et al. The survival benefits of AIDS treatment in the United States. J Infect Dis. 2006;194:11-19.
2. Roling J, Draenert R, Goebel FD. Options in HIV therapy:present and future. National Center for Biotechnology Information (NCBI). Accessed August 7, 2006. Originally published in German, in: Internist (Berl). 2005;46:892-894, 896-898. Abstract.
3. Khalsa AM. Preventive counseling, screening, and therapy for the patient with newly diagnosed HIV infection. Am Fam Physician. 2006;73:271-280.
4. Westby M, van der Ryst E. CCR5 antagonists: host-targeted antivirals for the treatment of HIV infection. Antivir Chem Chemother. 2005;16:339-354.
5. Castagna A, Biswas P, Beretta A, Lazzarin A. The appealing story of HIV entry inhibitors: from discovery of biological mechanisms to drug development. Drugs. 2005;65:879-904.
6. Agrawal L, Lu X, Jin Q, Alkhatib G. Anti-HIV therapy: current and future directions. Curr Pharm Des. 2006;12:2031-2055.
7. Lederman MM, Penn-Nicholson AP, Cho M, Mosier D. Biology of CCR5 and its role in HIV infection and treatment. JAMA. 2006;296:815-826.
8. Leonard JT, Roy K. The HIV entry inhibitors revisited. Curr Med Chem. 2006;13:911-934.
9. Department of Health and Human Services (DHHS). Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Available at: www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf Accessed October 23, 2006.
10. Markovic I. Advances in HIV-1 entry inhibitors: strategies to interfere with receptor and coreceptor engagement. Curr Pharm Des. 2006;12:1105-1119.
11. Harrington RD, Spach DH. HIV and AIDS. Infect Dis. 2006;33:1-28.
12. Moyle GJ, Wildfire A, Mandalia S, et al. Epidemiology and predictive factors for chemokine receptor use in HIV-1 Infection. J Infect Dis. 2005;191:1-7.
13. Reeves JD, Piefer AJ. Emerging drug targets for antiretroviral therapy. Drugs. 2005;65:1747-1766.
14. Poveda E, Briz V, Quiñones-Mateu M, Soriano V. HIV tropism: diagnostic tools and implications for disease progression and treatment with entry inhibitors. AIDS. 2006;20:1359-1367. Co-receptor CD4 + cell surface
15. Flint SJ, Enquist LW, Krug RM, Racaniello VR, Skalka AM. Reverse transcription and integration: Hallmarks of the Retroid Viruses. In: Principles of Virology: Molecular Biology, Pathogenesis, and Control. Washington, DC: ASM Press; 2000:199-234.
16. Young JAT. The replication cycle of HIV type 1. In: Cohen PT, Sande MA, Volberding PA, et al, eds. The AIDS Knowledge Base. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 1999:141-148.
17. National Institute of Allergy and Infectious Diseases. How HIV causes AIDS. Available at: http://www.niaid.nih.gov/factsheets/howhiv.htm. Accessed October 23, 2006.
18. Flint SJ, Racaniello VR, Enquist LW, Skalka AM. Attachment and entry. In:Principles of Virology: Molecular Biology, Pathogenesis, and Control of Animal Viruses. 2nd ed. Washington, DC: ASM Press; 2004:127-180.
19. Berger EA, Doms RW, Fenyö EM, et al. A new classification of HIV. Nature. 1998;391:240.
20. Brumme ZL, Goodrich J, Mayer HB, et al. Molecular and clinical epidemiology o f CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. J Infect Dis. 2005;192:466-474.
21. Demarest J, Bonny T, Vavro C, et al. HIV-1 co-receptor tropism in treatment naive and experienced subjects. Presented at Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Washington, DC. October 31, 2004. Abstract H-1136.
22. Whitcomb JM, Huang, W, Fransen S, et al. Analysis of baseline Enfuvirtide (T20) susceptibility and co-receptor tropism in two-phase III study populations. Presented at Conference on Retroviruses and Opportunistic Infections (CROI). Boston, MA. February 10-14. Abstract 557.
23. Wilkin T, Su Z, Kuritzkes D, et al. Co-receptor tropism in patients screening for ACTG 5211, a phase 2 study of vicriviroc, a CCR5 inhibitor. Presented at Conference on Retroviruses and Opportunistic Infections (CROI). Denver, CO. February 5-8, 2006. 655. Abstract.
 |
 |
|
|
Copyright © 2006, 2007 Pfizer Inc. All rights reserved. The information provided in this site is intended only for healthcare professionals in the United States.
Home Contact Us Terms of Use Privacy Policy Unsubscribe
|
|
  | MV279310B |
|
|